Advaxis has invented an innovative immunotherapy technology for treating various cancers and other diseases. The company's primary therapeutic target is HPV related cancer, such as cervical cancer. Advaxis has a preclinical program with various immunotherapies in development for cancers and infectious diseases, and is currently conducting a series of clinical trials. Over 15 distinct constructs are in various stages of development, either directly by the company or through strategic collaborations with recognized centers of excellence.
HPV (human papillomavirus) is a common virus, with over 120 currently identified types. It is considered the most common sexually transmitted infection in the U.S., and most people will face some type of HPV infection during their life. Infection is more common in women than in men, and some estimates are that 80% of women will get the virus at some point, although HPV infections are usually temporary, with few side effects.
Most HPV infections are harmless, but a small percentage of HPV infections don't go away, and repeated infections can, if not treated, result in cervical and other types of cancer. Although such cancers can be successfully treated if identified in time, such treatments are less available in many parts of the world, and there are hundreds of thousands of unnecessary deaths from cervical cancer worldwide. As a result, cervical cancer is, on a worldwide basis, the second most common cancer in women, and the fifth deadliest. There is a huge market in Asia and South America.
The Advaxis patent-protected immunotherapy approach offers a superior treatment for developed cervical cancer, based upon a unique technology using live, attenuated bacteria that are bio-engineered to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG).
For additional information, visit Advaxis.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net